PINPOINT
LIVE

Serial Number

88768179

Owner

REVVITY DISCOVERY LIMITED

Attorney

Kevin A. Oliver

Filing Date

Jan 21, 2020

Add to watchlist:

No watchlists yet
View on USPTO

PINPOINT Trademark

Serial Number: 88768179 • Registration: 6325211

PINPOINT is a trademark filed by REVVITY DISCOVERY LIMITED on January 21, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

REVVITY DISCOVERY LIMITED (9 trademarks)

8100 CAMBRIDGE RESEARCH PARK, WATERBEACH
CAMBRIDGE CB25 9TL , GB

Entity Type: 24

Horizon Discovery Limited

8100 Cambridge Research Park, Waterbeach
Cambridge CB259TL , GB

Entity Type: 24

Trademark Details

Filing Date

January 21, 2020

Registration Date

April 20, 2021

Published for Opposition

February 2, 2021

Goods & Services

Biological preparations in the nature of eukaryotic cells, isogenic cell lines and bio-production cell lines generated using base editing engineering for scientific, laboratory or medical research; reagents, plasmids and assays for scientific, genetic and medical research; genomic reference control samples for medical laboratory use; molecular biology research tools, in the nature of chemical, biological and biochemical reagents; biological preparations in the nature of separate base editing components including mRNA, rRNA, gRNA, deaminase, nickase, ribonucleotide protein (RNP) for use in scientific, laboratory or medical research; biological preparations in the nature of genetically modified cells and vectors for scientific and research purposes; biological and chemical reagents including complexes of these molecules for research and for clinical and industrial use

Diagnostic preparations and materials generated by the use of base editing components for medical purposes; chemical preparation for use in DNA analysis for medical purposes; biological preparations in the nature of DNA, RNA and parts thereof for medical purposes; biological preparations in the nature of DNA extracts for medical purposes; biological preparations in the nature of gene editing enzymes for medical purposes; biological preparations in the nature of protein cell lysates, genomic DNA preparations and Formalin Fixed, Paraffin Embedded (FFPE) engineered tumour tissue mimics for medical diagnostic use; biological preparations in the nature of biological, biochemical and chemical reagents, including living cells, genetically modified cells and vectors, genomic DNA, cell cultures and mutant and normal isogenic cell line pairs, peptides, proteins and nucleic acids or complexes of these molecules for medical use; all the aforesaid goods being medical preparations

Treatment of biopharmaceutical materials; custom manufacture of cells and vectors for diagnostic, medical and commercial applications in relation to cell and gene therapies; consultancy and advisory services relating to the aforesaid services

collections of DNA and gene sequences for research and reference purposes provided as DNA microarrays and DNA chips

Custom cell-line engineering services; gene base-editing services for research purposes; gene engineering services; research and development services in the creation of databases or collections of information on biologicals including cells and cell lines for research purposes; creating and providing databases or collections of information on normal and mutated genes for research purposes; providing DNA reference standards for research purposes; providing DNA reference databases being collections of DNA and gene sequences for research purposes; research on cell line models; contract research on cell line models; research and development services relating to targeting therapies to individuals; establishing patient genotypes for research or analysis purposes; research and development services relating to combining therapies for individuals; research and development relating to reagents; disease modelling for research purposes; design of clinical trials for research purposes; research and development in re-positioning existing drugs from other therapeutic indications; consultancy and advisory services relating to the aforesaid services; all of the aforesaid services relating to biological and medical research and research and development in the field of cells and cell therapies, genome editing, genetic engineering and gene therapies

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Apr 20, 2026 REM1
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Mar 5, 2025 ASGN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 12, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jul 12, 2024 ECDR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Jul 12, 2024 EWOR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 12, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 12, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jul 12, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 12, 2024 COAR
REGISTERED-PRINCIPAL REGISTER
Apr 20, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 2, 2021 NPUB
PUBLISHED FOR OPPOSITION
Feb 2, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 13, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 28, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 26, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 26, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 26, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 29, 2020 GNRN
NON-FINAL ACTION E-MAILED
Sep 29, 2020 GNRT
NON-FINAL ACTION WRITTEN
Sep 29, 2020 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 28, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 26, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 26, 2020 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 4, 2020 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 4, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 4, 2020 REAP
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 9, 2020 GNRN
NON-FINAL ACTION E-MAILED
Apr 9, 2020 GNRT
NON-FINAL ACTION WRITTEN
Apr 9, 2020 CNRT
ASSIGNED TO EXAMINER
Apr 8, 2020 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Mar 30, 2020 AMPX
ASSIGNED TO LIE
Mar 26, 2020 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
Mar 20, 2020 PARI
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 25, 2020 NWOS
NEW APPLICATION ENTERED
Jan 24, 2020 NWAP